Recombinant Anti-CD89 x Anti-EGFR Bispecific Antibody (Triple Body)  (TRIB-132)

Recombinant Anti-CD89 x Anti-EGFR Bispecific Antibody (Triple Body) is designed to be expressed as two polypeptide chains respectively. The Fd fragment and LC from an anti-CD89 antibody are both extended with the scFv fragment from an anti-EGFR antibody. This BsAb can retarget macrophages to tumor cells. It is designed for the research of Head and neck cancer; Colorectal cancer (CRC); Glioblastoma multiforme (GBM); Squamous cancer; Non-small cell lung cancer (NSCLC); Solid tumors therapy.

Datasheet